September 29, 2016 7:13 AM ET


Company Overview of PaxVax Corporation

Company Overview

PaxVax Corporation researches, develops, manufactures, and commercializes vaccines against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; Vivotif, a typhoid fever vaccine for oral administration; Epaxal, a vaccine for hepatitis A; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain; and Ad4-mGag, a HIV vaccine component that expresses an optimized HIV gag protein. The company also engages in the research and dev...

900 Veterans Boulevard

Suite 500

Redwood City, CA 94063

United States

Founded in 2006





Key Executives for PaxVax Corporation

Chief Executive Officer, President and Director
Chief Financial Officer
Age: 64
Chief Scientific Officer and Executive Vice President
Chief Legal Officer and Executive Vice President
Chief Medical Officer
Age: 77
Compensation as of Fiscal Year 2016.

PaxVax Corporation Key Developments

PaxVax, Inc. Appoints Philip K. Moody as Chief Financial Officer

PaxVax Inc. announced the appointment of Philip K. Moody as Chief Financial Officer (CFO) effective August 29, 2016. In this role, Mr. Moody will oversee all financial functions for the company. Mr. Moody joins PaxVax from BTG PLC, where he served as the Chief Financial Officer for the North American sector. In this role, he served as an advisor to the Head of North America at BTG, and was responsible for management and oversight of all financial functions for the British-based medical device/specialty pharmaceutical business. Mr. Moody has also held senior finance roles in a number of public and private companies, including Chiron, where he was involved in their vaccines business and served as Vice President, Finance and Operations.

PaxVax Enters into Marketing and Distribution Agreement with Seqirus

PaxVax, announced that the company has entered into a marketing and distribution agreement with Seqirus. Under the terms of this agreement, PaxVax will market, sell and distribute two of Seqirus’ influenza vaccine products in Switzerland, Agrippal® (surface antigen, inactivated) and Fluad™ (influenza vaccine, adjuvanted). Agrippal is an inactivated trivalent influenza virus vaccine indicated for adults and children older than 6 months. Fluad is an adjuvanted trivalent inactivated influenza vaccine indicated for adults 65 years and older.

U.S. Food and Drug Administration Accepts Biologics License Application for Paxvax’s Single-Dose Oral Cholera Vaccine Vaxchora

PaxVax Inc. announced that the FDA has granted Vaxchora priority review status. If licensed, Vaxchora would be the only vaccine in the U.S. against cholera and PaxVax’s second FDA-licensed vaccine after Vivotif (typhoid fever vaccine). The BLA, which was submitted on October 16, 2015, is based on successful results from a 10 and 90-day cholera challenge trial, as well as two other safety and immunogenicity trials in healthy adults. More than 3,000 participants were enrolled in the phase 3 trials that evaluated Vaxchora at sites in Australia and the United States. Vaxchora also successfully met the Phase 3 primary endpoints and demonstrated efficacy in an immunogenicity study of older adults 46 to 64 years of age. The FDA’s action date for the Vaxchora BLA is June 15, 2016. The cholera strain used in Vaxchora is CVD 103-HgR, which was in-licensed from the University of Maryland School of Medicine’s Center for Vaccine Development in 2010. If approved, Vaxchora will be commercialized through the existing PaxVax marketing and sales infrastructure, which currently commercializes Vivotif.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
December 8, 2015

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PaxVax Corporation, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at